Recombinant Human Anti-BCMA x Human Anti-TACI Bispecific Antibody (IgG-Fv) (BSGV-H201)

Recombinant Anti-BCMA x Anti-TACI Bispecific Antibody (IgG-Fv) is formed by an Immunoglobulin G (IgG) and a fragment variable Fv region, in which the Fc of IgG is engineered by KIH. The Fv region of an anti-BCMA antibody variable domain is fused to the C terminal of an IgG of anti-TACI antibody, or vice versa. The format retains desired characteristics of intact antibodies. This BsAb can bind two receptors simultaneously. It is designed for the research of Lymphoma therapy.

Datasheet INQUIRY

Specifications

Targets

BCMA & TACI

Type

IgG-Fv

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Lymphoma

Targets

Target 1

BCMA

Gene ID

608

UniProt ID

Q02223

Alternative Names

TNFRSF17; tumor necrosis factor receptor superfamily, member 17; BCM; BCMA; CD269; TNFRSF13A; tumor necrosis factor receptor superfamily member 17; B-cell maturation factor; B cell maturation antigen; B-cell maturation protein

Target 2

TACI

Gene ID

23495

UniProt ID

O14836

Alternative Names

TNFRSF13B; tumor necrosis factor receptor superfamily, member 13B; CVID; RYZN; TACI; CD267; CVID2; IGAD2; TNFRSF14B; tumor necrosis factor receptor superfamily member 13B; tumor necrosis factor receptor 13B; transmembrane activator and CAML interactor

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-BCMA x Human Anti-TACI Bispecific Antibody (IgG-Fv) (BSGV-H201). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-BCMA x Human Anti-TACI Bispecific Antibody (IgG-Fv) (CAT#: BSGV-H201)

Specifications

Targets

Customer Reviews and Q&As